Pharmaceutical Cannabinoids: A Company Update

Time: 12:00 pm
day: Day One Track B - morning

Details:

  • Examine re-purposing dronabinol for the treatment of obstructive sleep apnea (OSA) and other indications
  • Explore completion of two successful phase 2 clinical trials in OSA
  • Develop lipid nanoparticle formulation to overcome current dronabinol limitations

Speakers: